Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

FDA approves Ferriprox to treat transfusional iron overload due to sickle cell disease

May 3, 2021

European Commission approves Orladeyo for the prevention of HAE attacks

May 3, 2021

Hillhurst cleared by FDA to begin phase I study of HBI-002 for sickle cell disease

April 28, 2021

FDA removes clinical hold on uniQure's hemophilia B gene therapy program

April 27, 2021

Fulcrum Therapeutics' FTX-6058 could be a disease-modifying treatment for sickle cell disease

April 26, 2021

FDA places clinical hold on proposed phase II study of KVD-824

April 21, 2021

Enrollment ongoing in phase I/II study of EXG-34217 in patients with bone marrow failure

April 15, 2021

Biotest adds additional patient group to ongoing phase III AdFIrst study of BT-524

April 8, 2021

FDA clears initiation of first-in-human study of CRISPR_SCD-001 for sickle cell disease

March 31, 2021

Phase II trial of IONIS-PKK-LRx as treatment for HAE meets endpoints

March 30, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...